Haleon plc (HLN)
Automate Your Wheel Strategy on HLN
With Tiblio's Option Bot, you can configure your own wheel strategy including HLN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HLN
- Rev/Share 1.2188
- Book/Share 1.7603
- PB 2.3928
- Debt/Equity 0.6249
- CurrentRatio 0.9838
- ROIC 0.0571
- MktCap 37860310696.824
- FreeCF/Share 0.0
- PFCF 0.0
- PE 26.8253
- Debt/Assets 0.2944
- DivYield 0.0148
- ROE 0.0871
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | HLN | BNP Paribas Exane | Neutral | Outperform | -- | $13.4 | May 27, 2025 |
| Upgrade | HLN | Morgan Stanley | Equal Weight | Overweight | -- | $11.25 | May 9, 2025 |
| Downgrade | HLN | HSBC Securities | Buy | Hold | -- | -- | March 5, 2025 |
| Downgrade | HLN | Morgan Stanley | Overweight | Equal Weight | -- | -- | Jan. 10, 2025 |
| Downgrade | HLN | Bernstein | Outperform | Market Perform | -- | -- | Jan. 8, 2025 |
News
Whitening without the pain: Sensodyne Clinical White gives Canadians a reason to smile
Published: May 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sensodyne launches new premium Clinical White toothpaste to brighten Canadians' smiles in time for National Smile Day. Sensodyne launches new premium Clinical White toothpaste to brighten Canadians' smiles in time for National Smile Day.
Read More
Consumer healthcare group Haleon raises medium-term profit forecast
Published: May 01, 2025 by: Reuters
Sentiment: Positive
Haleon on Thursday raised its medium-term target for profit growth from 2026, banking on strength in key markets and costs cuts within its supply chain, which would save the consumer healthcare group 800 million pounds ($1.07 billion) in the next five years.
Read More
Haleon shares hit by weaker US vitamin sales
Published: April 30, 2025 by: Proactive Investors
Sentiment: Negative
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 1% after the toothpaste and painkillers maker reported slightly stronger first-quarter growth than expected but saw a weaker performance than expected from its vitamins, minerals and supplements (VMS) arm in America. The FTSE 100 group posted a Q1 update showing 3.5% organic revenue growth, supported by positive contributions from all product categories and regions, beating an average City forecast of 3.3%.
Read More
Haleon reports lower first-quarter revenue hurt by a weaker flu season
Published: April 30, 2025 by: Reuters
Sentiment: Negative
British consumer healthcare group Haleon on Wednesday reported a 2.3% fall in its first-quarter revenue as sluggish demand for its cold and cough medicines outside of North America continued to weigh.
Read More
Does defensive Haleon have a cure for the current market blues?
Published: April 09, 2025 by: Proactive Investors
Sentiment: Positive
Citi believes Haleon PLC (LSE:HLN, NYSE:HLN) is well positioned for the current uncertain climate, describing the consumer healthcare group as a solid defensive play for investors concerned about recession risks and the fallout from Donald Trump's new tariff regime. Shares in the maker of household brands such as Sensodyne and Panadol, have been under pressure amid broader worries over US consumer demand and a tough comparison with last year's strong flu season.
Read More
Pfizer to dispose of entire Haleon stake
Published: March 18, 2025 by: Reuters
Sentiment: Neutral
Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.
Read More
Haleon: Investors unimpressed by growth target and £500m buyback as shares slide 3.2%
Published: February 27, 2025 by: Proactive Investors
Sentiment: Negative
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 3.2% in early trading as investors saw little in the results to justify further gains at current valuations. While full-year sales and profits met expectations, analysts noted a lack of clear catalysts.
Read More
Haleon results could provide tonic for investor anxiety, says Barclays
Published: February 25, 2025 by: Proactive Investors
Sentiment: Positive
When Haleon PLC (LSE:HLN, NYSE:HLN) reports results on Thursday, 27 February, Barclays expects its sales of painkillers to have offset the "well known headwind" from a weak start to the cold and flu season in the final quarter of 2024. Analysts at the bank said that earnings delivery and profit margin expansion are the main areas of focus for investors in the FTSE 100 consumer health products group too, while Futura Medical investors are likely to be keeping an eye out for news on the Eroxon collaboration.
Read More
About Haleon plc (HLN)
- IPO Date 2022-07-25
- Website https://www.haleon.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Brian James McNamara
- Employees 24561